RYTELO is a first-in-class oligonucleotide telomerase inhibitor that is approved in the US for adult patients with low-to-intermediate-1 risk LR-MDS with transfusion-dependent anemia requiring 4 or ...

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and ...

A panelist emphasizes that treatment decisions for anemia in low-risk myelodysplastic syndrome should be guided by symptoms ...

Myelodysplastic syndromes (MDS) are a group of disorders that typically arise in adulthood, especially after the age of 70, and their five-year survival rate is around 30%. MDS are characterized by ...

More information: Cesare Rollo et al, VAE-Surv: A novel approach for genetic-based clustering and prognosis prediction in myelodysplastic syndromes, Computer Methods and Programs in Biomedicine ...

SAN DIEGO — Genetic mutations related to myelodysplastic syndrome occurred significantly more often among people who smoked than nonsmokers, according to study results presented at ASH ...

If you have myelodysplastic syndromes (MDS), your doctor may take a "watch and wait” approach, which may cause you anxiety and fear. These tips can help you cope.

Clinical trials for myelodysplastic syndromes (MDS) may offer a way to explore emerging treatments since traditional therapies may not work for everyone.

Drs. Patnaik and Xie discuss the discovery of VEXAS syndrome and how it differs from classical myelodysplastic syndrome.

In Myelodysplastic Syndromes, Does Survival Differ in Black and White Patients? —In this study, Black individuals were found to have better overall survival from myelodysplastic syndromes than ...

A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS).

Novel treatment options in lower- and higher-risk patients with myelodysplastic syndromes and a promising targeted therapy are among MDS highlights from ASCO 2022, as discussed by Dr Amy DeZern.